How Enterprises Do Pharmaceutical Investment and How to Deal with the Reform of Medical Reform System

In the next five years, pharmaceutical investment merchants are a critical period for deepening the goal of health system reform, and they are also critical for the adjustment of pharmaceutical distribution industry structure and transformation of development methods. The pharmaceutical commercial market will undergo major changes, and the small and medium-sized pharmaceutical and commerce industries will basically face fierce competition. In the competition, elimination, transformation, acquisition, mergers, holding, or reorganization, of course, there are also some small and medium-sized pharmaceutical and commerce businesses that have obvious competitive advantages in the region. However, commercial resources must be pooled, and market competition will shift from the chaos of marketization of pharmaceutical investment to the disorder of policy.

First of all, from the current point of view, the situation of the sales of Class I vaccines and the sales of Class II vaccines of the China Health Group is not optimistic. In particular, the sale of one class of seedlings has weakened as a whole. After the integration and reorganization of the Zhongsheng Group, what needs to be done is to increase the efficiency of the use of its own resources and accelerate the pace of change in the marketing and management of one type of vaccine. At the same time, it is necessary to strengthen the sales of the second type of vaccine and use market-based competitive advantages and government resource advantages to systematically control the real The Chinese vaccine market has changed from the traditional model of small profits and quick turnover to the service-oriented modern business. It has changed from a crude business concept to a refined management, and has changed from a single-practice drug investment attraction to a diversified one.

Second, since the drug R&D capabilities of domestic pharmaceutical investment enterprises have generally weakened over the years, this situation will not change in the short term, and homogenous competition will continue. However, in the future there will be general market homogenization competition and state-owned monopoly commercial homogenization. At the same time, competition has emerged. Due to the rapid development of state-owned monopoly businesses, the monopoly of state-owned monopoly businesses in the pharmaceutical and medical services market will be amplified. The homogenization of state-owned monopoly businesses in the future will be reduced compared with the homogenization of the general market.

Finally, with the rapid development of state-owned monopoly medicines and business commerce, future drug prices will become more expensive due to the existence of pharmaceutical business overlords with inefficient management. From one-way information to full-scale front-end pharmaceutical back-end medical information matching and transfer transformation, from a single business to the front-end pharmaceutical back-end retail mergers, and gradually formed a consortium. In the future, the pharmaceutical business model will be multiple, and it will be more competitive, more meticulous, and professional.